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Vasopressin (VP),' or antidiuretic hormone
(ADH), is the single most important hormonal regu-
lator of the renal handling of water in mammals.
Impressive progress in elucidating the mode of action
of this hormone at the cellular level was made pos-
sible in recent years mainly by two developments:
insights into the biochemistry of polypeptide hor-
mone action in general and use of various micro-
methods for the study of single nephron segments.
Work utilizing the latter approach, which has yielded
a wealth of information about possible modes of
water and solute permeation in VP-responsive epi-
thelia, has been lucidly summarized in several recent
reviews [1—4]. In the present article, we shall therefore
focus attention on the biochemical aspects of VP
action [2, 5, 6]. Moreover, even though much useful
information has been obtained on nonmammalian
membranes, we shall focus our discussion mainly,
though not exclusively, on experiments performed on
mammalian kidneys.
Biochemical steps, which are currently thought to
be involved in the cellular action of VP that leads to
an increase in water permeability [2, 5, 6], are roughly
schematized in Fig. I. In the mammalian kidney VP
acts on the collecting ducts and on functionally sim-
ilar late segments of distal convoluted tubules. The
hormone binds onto a specific receptor located in the
basal and/or lateral plasma (i.e., cell) membrane
(also often called the basolateral, serosal or pen-
tubular plasma membrane). The interaction of VP
with its specific receptor stimulates enzymatic forma-
tion of cyclic adenosine 3', 5'-monophosphate (cyclic
AMP), which serves as an intracellular mediator of
VP action. Cyclic AMP, in turn, directly or indirectly
elicits an increase in the water permeability of the
luminal (also called apical or mucosal) membrane
and possibly of adjacent intercellular structures.
Not exclusively the variety that is native to most mammals,
namely, [8-arginine]-vasopressin.
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Thus, in the following discussion, we have divided the
cellular actions of VP into two major sequential bio-
chemical events: (a) the interaction of the hormone
with its receptor and the effect of this reaction on
cyclic AMP metabolism and (b) the reactions by
which cyclic AMP, in turn, may elicit changes in
water permeability (Fig. 1).
Effects of VP on cyclic AMP metabolism
VP-receptor interactions. That VP probably acts
only when presented to the peritubular surface of the
cell was first suggested by the lack of an antidiuretic
effect when the hormone was injected retrograde into
the collecting system of rat kidneys [7]. This notion
has been upheld by experiments on isolated, perfused
collecting tubules [8, 9], which showed an increase in
water permeability only when VP was put into the
bathing medium but not when it was added to the
luminal perfusate. These studies strongly suggest, al-
though they do not prove, that the receptor for VP is
located in the basal or lateral membranes or in both.
Evidence for the binding of VP to hormone-re-
sponsive renal cells was first suggested by the autora-
diographic studies of Darmady et al [10]. Specific
binding of [3H]-vasopressin to plasma membranes of
the renal medulla was then shown independently by
two laboratories [11, 12], but neither study localized
the binding specifically to peritubular as opposed to
luminal membranes of collecting ducts nor even to
plasma membranes belonging only to renal med-
ullary cells that respond to VP. Nevertheless, when
coupled with the studies cited earlier [8—10], the evi-
dence certainly seems to favor the location of VP-
specific receptors in the basal or lateral plasma mem-
branes or in both. A further question that is not yet
settled is whether VP, in addition to combining with
its receptor at the surface of cells, also needs to pene-
trate the cells. By analogy with the action of other
hormones on other target tissues [13—16], including
polypeptides, one would predict that VP need not
enter cells in order to exert its functional effect.
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Fig. I. Two major steps in the action of VP on the cell of a mamma-
lian collecting duct. A, VP-dependent formation of cyclic AMP:
information carried by VP is transmitted through the basal or
lateral plasma membrane or through both to the intracellular
"second messenger", cyclic AMP. B, Cyclic AM P-induced change
in water permeability: cyclic AMP elicits specific changes in the
luminal plasma membrane, which alters the water permeability of
that barrier. VP, vasopressin. cAMP, cyclic AMP, LuPM, luminal
plasma membrane: denotes the cell membrane facing the lumen of
a renal tubule or of the amphibian urinary bladder; it is in contact
with tubular fluid or bladder urine. This membrane is also called
the "apical" or "mucosal" plasma membrane, mostly in reference
to amphibian tissues. BaPM, basilar plasma membrane: denotes
the cell membrane covering the rest of the cell; it is in contact with
interstitial fluid. This membrane is also called the "basolateral"
membrane because it includes portions that face not only the
basement membrane but also adjacent cells. Basal and lateral
aspects of this membrane appear to have similar permeability and
morphological properties. Other synonyms used for BaPM are
"antiluminal", "peritubular" and "serosal" membrane.
VP-sensitive adenylate cyclase. In the cell mem-
bran; the VP receptor is associated with adenylate
cyclase, an enzyme that catalyzes the formation of
cyclic AMP from adenosine triphosphate (ATP) [17].
The VP receptor-enzyme system is a complex bio-
chemical entity, which is frequently referred to in a
concise way as "VP-sensitive adenylate cyclase". Of
its two major components, the VP receptor and the
adenylate cyclase [13, 17], the latter is also referred to
as the "catalytic subunit". The VP receptor is prob-
ably located 'on the outer surface of the plasma mem-
brane, while the adenylate cyclase, or at least its
catalytic center, faces the interior of the cell (Fig. 2).
The biochemical characteristics of VP-sensitive
adenylate cyclase are just being clarified. Although
the mechanism of association of the VP receptor with
the adenylate cyclase is not known, the dissociation
of these two components, as well as their apparent
solubilization was recently achieved using a plasma
membrane fraction from porcine renal medulla. Tn-
ton X-l00, a nonionic detergent, was used in this
study, and the VP receptor was identified by binding
of tritiated [3H]-VP [18]. Such findings suggest that
association of the VP receptor with adenylate cyclase,
and possibly with, other components of the mem-
brane, may involve hydrophobic interactions with
lipids or hydrophobic membrane proteins.
Solubilization of adenylate cyclase from whole
renal medulla of rats, using the detergents Lubrol
PX, Lubrol WX or Triton X-l00, has also been de-
scribed [19, 20]. The predominant solubilized form of
the rat enzyme had an estimated mol wt of about
159,000 daltons, and it appeared that no more than
5% of its surface is involved in the hydrophobic inter-
actions with other components of the membrane [21].
It should be kept in mind, however, that these mo-
lecular characteristics of adenylate cyclase may not
apply specifically to the VP-sensitive variety of the
enzyme. The whole renal medulla was taken as the
starting material in the above studies, and renal mcd-
ullary tissue probably also contains other adenylate
cyclases that are associated with receptors for other
hormones [22—25].
Occurrence and location within the kidney. VP-sen-
sitive adenylate cyclase has been found in all mam-
malian species that have been studied thus far [5, 6,
22, 25—27], including man [6, 25, 28]; among non-
mammalian vertebrates its occurrence may be limited
to amphibians [29].
Chase and Aurbach [26] showed that most of the
adenylate cyclase that is stimulated by VP is located
in the renal medulla, while a much smaller portion
can be detected in the renal cortex. The latter presum-
ably is located in cortical collecting ducts and late
parts of the distal convoluted tubules [30, 31]. Morel,
Chambardès and Imbert and Imbert et al [30, 31]
recently applied a microdissection method for local-
izing hormone-sensitive adenylate cyclases to various
nephron segments of rabbits. As expected, the highest
activities elicited by VP were found in collecting
ducts. There was also, however, prominent VP-stimu-
lated activity in the outer medullary and cortical por-
tions of the ascending limbs of Henle's loops, al-
though the threshold and half-maximal doses of VP
required for this stimulation were higher than in col-
lecting ducts [31]. This interesting finding suggests
that a possible effect of VP on the loops of Henle
should be reevaluated. Although, in general, there
has been no detectable influence of VP within the
loops [1], Imai and Kokko [32] reported a small VP-
induced increase in the water permeability of thin
ascending limbs of Henle in rabbits—the same spe-
cies that was studied by Morel et al and Imbert et al
[30, 31].
As to the subcellular site of VP-sensitive adenylate
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Fig. 2. Schema of the current view on the cellular
action of vasopressin. AC, adenylate cyclase;
ADP, adenosine 5'-diphosphate; 5' AMP, adeno-
sine 5'-monophosphate; ATP, adenosine 5'-tri-
phosphate; C, coupling component of adenylate
cyclase; GP, glycogen phosphorylase; MF, mi-
crofilaments; MT, microtubules; LuPM, luminal
plasma membrane; p. phosphate attached to
protein; cyclic AMP, cyclic adenosine 3',5'-mono-
phosphate; P DIE, cyclic AM P phosphodiesterasc;
PK, cyclic AMP-dependent protein kinase; P1,
inorganic phosphorus; PP, pyrophosphate; PPase,
protein phosphatase; R, receptor for vaso-
pressin; TJ, tight junction; VP, vasopressin
molecule. Loci showing water penetration through
the LuPM do not necessarily mean structural
pores but only areas in the membrane where
water flux increases as a consequence of the
action of cyclic AMP.
cyclase, the tissue fractionation studies on bovine
renal medulla localize the highest activity in the
plasma membrane fraction as compared to other
membranes or soluble components [33]. High activity
of VP-dependent adenylate cyclase was also found in
the plasma membrane fraction of the renal medulla
of rats, cows and pigs [II, 12, 20, 24, 33—35].
Relationship between VP structure and action.
Many chemical analogs of VP and other neurohy-
pophysial hormones have been used to study the
relationship between the chemical structure of a given
compound and its biological effect, as measured ei-
ther in whole animals or in isolated organs [36]. The
same type of question has also been investigated us-
ing VP-sensitive adenylate cyclase in vitro [27, 37—42].
With few exceptions, such studies have shown a re-
markable parallelism between the ability of the ana-
logs to activate renal medullary adenylate cyclase in
vitro (assessed as the dose required for the half-max-
imal response, or Km), and their ability to elicit an
antidiuretic response in the same species in vivo [34,
37—43]. Apparent exceptions to this rule may have
been caused by differences in the bioavailability of a
given analog [44], perhaps mostly because of differ-
ences in the rate of their breakdown; that is, the
exceptions were evidently unrelated to the affinity of
the compound for the VP receptor (see following).
The parallelism between the ability of a compound
to activate adenylate cyclase and the degree of its
antidiuretic effect has also been supported by findings
from comparative studies, In various species of mam-
mals, for example, adenylate cyclase derived from the
renal medulla always was most sensitive to the type of
VP that is native to the species [27, 34, 37, 39, 43].
Thus, in all mammals examined in which [8-argi-
nine]-vasopressin is the natural and most effective
antidiuretic hormone, the renal medullary adenylate
cyclase was most sensitive to that peptide; in contrast,
the enzyme derived from porcine kidneys was most
sensitive to [8-lysine]-vasopressin, which is the native
and most effective antidiuretic hormone in pigs [37,
39]. And [8-arginine]-vasotocin, the VP analog that is
native to amphibians, appears to be more effective
than [8-arginine]-vasopressin in stimulating the renal
adenylate cyclase from frogs and toads [29].
In extensive studies with a large number of ana-
logs, Jard et al [12, 18, 39—43] have analyzed the
relationship between the ability of VP to activate
adenylate cyclase and its capacity to bind onto recep-
tors in the plasma membrane. In general, they found
a striking similarity between the structural require-
ments for attachment to the receptor and the activa-
tion of adenylate cyclase. The kinetics of these reac-
tions were also carefully analyzed in these studies; the
analysis suggests that activation of the enzyme is a
nonlinear function of VP-binding onto the receptors
[12, 39, 41, 42] and that it may be related to occu-
pancy of the receptors [12, 41]. The onset of adeny-
late cyclase activation by VP appears to be very fast,
and it is rapidly though not instantaneously reversed
when the concentration of VP is decreased [12, 45].
Tissue concentration of cyclic AMP and role of cy-
clic AMP phosphodiesterase. It is generally held that
the means by which VP-sensitive adenylate cyclase
ultimately effects changes in water permeability is by
increasing the concentration of cyclic AMP within
VP-responsive cells (Fig. 1). Efforts have been made,
therefore, to correlate the tissue content of cyclic
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AMP with the dose of VP to which the tissue was
exposed. The predicted relationship has been ob-
served in various isolated preparations from the renal
medulla: in cells [46], in tubular fragments [47, 48]
and in tissue slices [49—51]. It has been more difficult
to establish the relationship for the renal medulla in
situ, probably mainly because the overlying, rela-
tively thick renal cortex prevents instant freezing of
the medulla, after VP has been given. Such instant
freezing is most important for accurate measure-
ments of cyclic AMP concentrations [52]. Never-
theless, increases in the renal medullary content of
cyclic AMP after VP administration have been found
[53, 54], although a dose-response relationship has
not yet been reported. By means of an immunofluo-
rescent cytochemical technique [55], cyclic AMP has
been localized in VP-sensitive cells of the toad blad-
der [56] and of the mammalian kidney (Barnes LD,
Dousa TP, Ong SH, Steiner AL: unpublished ob-
servations); its exact location within the cell, how-
ever, is not yet known.
1. Cyclic AMP phosphodiesterase. Obviously the
tissue concentration of cyclic AM P is determined not
only by its rate of formation, catalyzed by VP-sensi-
tive adenylate cyclase, but also by its rate of break-
down and possibly by its efflux from cells. The break-
down of cyclic AMP is catalyzed by cyclic AMP
phosphodiesterase (PDIE) [57]. The importance of
this enzyme in VP-stimulated production of cyclic
AMP is exemplified by the fact that inhibition of
PDIE, as by methylxanthines, potentiates both the
tissue accumulation of cyclic AMP after VP admini-
stration as well as the functional response to the
hormone [2, 8, 9, 22]. The enzyme, as obtained from
the renal medulla, hydrolyzes cyclic AMP to 5 'AMP
at substrate concentrations ranging from l0- to l0-4M
[28, 33]. By analogy with other tissues [57], it may
be expected that several isoenzymes of PDIE exist in
the renal medulla. There is no evidence that VP itself
influences the activity of PDIE, either in vitro [58] or
in vivo [59].
Localization of PDIE has been attempted in rab-
bits by a histochemical technique. At a high substrate
concentration of l0-3M cyclic AMP, most of the ap-
parent PDIE activity was found in the loops of Henle
while very little was detected in the collecting ducts
[60]. This seemingly surprising finding might be ex-
plained by the fact that the predominant PDIE within
collecting ducts is of the high affinity-low K m variety
[57].
Factors influencing VP-dependent cyclic AMP
metabolism. A number of naturally occurring sub-
stances can modulate the tissue response to VP by
influencing either the formation of cyclic AMP
through VP-sensitive adenylate cyclase, or the break-
down of the nucleotide through cyclic AMP
phosphodiesterase.
I. Prostaglandins. These compounds, especially
prostaglandin E2 (POE2), are produced in large quan-
tities within the renal medulla [61]. Their influence on
VP-stimulated cyclic AMP has been studied quite
extensively, mostly in an indirect way by using ex-
ogenous prostaglandins or agents that influence the
production or action of endogenous prostaglandins.
From these studies, it can only be concluded that the
prostaglandins do modify the renal response to VP,
although by what means or in which direction is not
clear. One possible source for the confusion may be
the fact that the exogenous compound most fre-
quently used experimentally is one that does not oc-
cur naturally in the renal medulla, namely pros-
taglandin E1 (POE1).
Some studies suggest that POE1 decreases both the
accumulation of cyclic AMP [49] and the functional
response after VP administration [9] in the mamma-
lian renal medulla and in the toad bladder [2, 62]. On
the other hand, there is evidence that in the absence
of VP, POE1 may have in both mammals and am-
phibians the opposite effect: an increase in cyclic
AMP concentration [49, 63] and an increase in water
permeability [9, 63]. In still another instance, POE1
inhibited the VP-induced hydroosmotic effect, but
did not change the tissue concentration of cyclic
AMP [64]. These findings are puzzling, especially in
the case of the kidney where, unlike in other systems,
VP probably exerts only the single physiological ef-
fect of altering water permeability [1]. Experiments
on cell-free systems have thus far not helped to re-
solve the problem. While in some studies pros-
taglandins had a small to modest inhibitory effect on
renal medullary adenylate cyclase [49, 65, 66], in
other experiments they were found to stimulate the
enzyme [35, 49, 67]. This stimulatory effect appeared
to be additive to that exerted by VP [35, 67], which
suggests that at least in the mammalian renal medulla
there may exist a prostaglandin-sensitive adenylate
cyclase which is distinct from that which is stimulated
by VP. This possibility may be one cause for the
apparent paradox of prostaglandins having at times
either an inhibitory or a stimulatory influence; i.e.,
the former might be exerted on VP-sensitive adeny-
late cyclase, while the latter might be effected through
a separate system [63].
It is also conceivable that the inhibitory influence
of prostaglandins E on VP-sensitive adenylate cyclase
is due not to the prostaglandins £ themselves, but to
the effect of their precursors, the prostaglandin endo-
peroxides (POEP). It has been shown for hormones
50 Dousa and Valtin
other than VP that PGEP's are potent inhibitors of
hormone-sensitive adenylate cyclases [68, 69], Fur-
thermore, inhibitors of prostaglandin synthetase,
such as indomethacin, acetylsalicylate or meclofena-
mate, block the synthesis not only of prostaglandins
but also of PGEP [68]. To the extent that these effects
can be extrapolated to VP-sensitive adenylate cyclase,
they suggest that compounds such as indomethacin
potentiate the increase in renal medullary cyclic AMP
after VP administration [54] and the antidiuretic ef-
fect of VP [70] by reducing or abolishing the inhi-
bition of VP-sensitive adenylate cyclase by PGEP's.
Interpretation of experiments involving prostaglan-
din synthetase inhibitors are further complicated
by the fact that indomethacin [71, 72], and pos-
sibly also fenamic acid derivatives [71], inhibit
PDIE and hence the breakdown of cyclic AMP. Fi-
nally, to complete the speculation, is it possible that
the inhibition of VP-sensitive adenylate cyclase by
high doses of exogenous prostaglandins might be due
to reverse synthesis of PGEP [73] from pro-
staglandins themselves? It may be consoling to realize
that the relationship between cyclic AMP and pros-
taglandins is also far from clear in other hormonal
systems [71].
2. Catecholarnines. As is the case with the pros-
taglandins, experiments to date do not permit a con-
clusive statement regarding the modulating influence
of the catecholamines on VP-sensitive adenylate cy-
clase. Several investigators [23, 24, 48, 74] have found
an adenylate cyclase in the renal medulla that is stim-
ulated by 13-adrenergic agents, and/or that these
agents cause an increase in the tissue level of cyclic
AMP. However, it is not clear whether this system is
located in the same cells or cell compartments as the
VP-sensitive adenylate cyclase of mammalian renal
medulla. Preliminary reports [75, 76] state that an
isoproterenol-sensitive adenylate cyclase is located
mainly in cortical rather than medullary segments of
the distal nephron, at least in the rabbit; and most of
the studies on the kidney in vivo suggest that the
antidiuretic effect of 13-catecholamines may not be
directly mediated through cyclic AMP [77].
Thus far, the story is similar for a-adrenergic com-
pounds, which in general were found to have inhib-
itory effects. They may inhibit VP-induced antidiur-
esis in vivo [77] as well as VP-elicited increases in the
tissue concentration of cyclic AMP [48, 74]. But these
effects have not yet been tested in isolated membrane
systems, and there is thus as yet no direct evidence on
whether a-catecholamines cause inhibition through
VP-sensitive adenylate cyclase.
3. Other hormones. Although adrenal steroids are
usually thought of as decreasing the water per-
meability of VP-sensitive renal membranes [78], it
has been shown that they potentiate the hydro-
osmotic effect of VP on the toad bladder [2, 79]. This
potentiation appears to involve inhibition of cyclic
AMP phosphodiesterase [80]. In studying the effect
of adrenal steroids on the renal medullary cyclic
AMP system, attention has thus far been focused on
the formation of the nucleotide rather than on its
breakdown. Adrenalectomy in rats decreased VP-
stimulated activation of renal medullary adenylate
cyclase [43], but did not influence the basal activity of
the cyclase nor its activity when stimulated by sodium
fluoride [43, 81]. The major impairment appeared to
be in the coupling between the VP-receptor complex
and the adenylate cyclase, with only a small impair-
ment in the binding of VP to its receptor [43]. Treat-
ment with dexamethasone corrected the entire defect,
whereas aldosterone reversed only the defect in VP
binding but not the major one of coupling [43].
Thyroid hormone appears to have a profound ef-
fect on the VP-sensitive adenylate cyclase system.
Both basal and VP-stimulated activity of renal mcd-
ullary adenylate cyclase was found to be markedly
lower in hypothyroid than in euthyroid rats, while
PDIE was not significantly different. Short-term
treatment with thyroxin restored the activity of the
adenylate cyclase and led to a decrease in PDIE activ-
ity, thus favoring tissue accumulation of cyclic AMP
[82]. These effects of thyroid hormone appear to be
specific for the renal medulla [83].
4. Electrolytes and urea. The high concentration of
certain solutes in the renal medulla raises the ques-
tion whether this rather unique interstitial composi-
tion might influence the cellular action of VP. In an
assay system in vitro, NaCl as well as KCI stimulate
VP-responsive adenylate cyclase at low concentra-
tions [28, 84, 85] and inhibit the enzyme at high
concentrations [84, 85]; urea has a slight inhibitory
effect [84]. Of these three solutes, the concentration
of urea in the renal medulla undergoes wide and
rather rapid swings during different functional states
and that of NaCI moderate fluctuations [86, 87]. The
concentration of KCI tends to stay relatively constant
although pathologic K deficiency may influence the
response to VP [6]. Although one cannot predict
intracellular, let alone subcellular, concentrations of
these solutes from results on tissue homogenates [86,
87], the possible modulatory influences of these
changes on the VP-dependent formation of cyclic
AMP should be borne in mind [84].
Of the divalent cations, Mg2 is a necessary cofac-
tor for both adenylate cyclase [17] and cyclic AMP
phosphodiesterase [57], as well as for other com-
ponents involved in the action of VP, e.g., protein
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kinase and microtubules [5, 6]. When used in high
concentrations (103M or greater), Ca2 inhibits
renal medullary adenylate cyclase [11, 66,90], as well
as the adenylate cyclases derived from the other tis-
sues [17]. It is not yet clear whether a minimal
amount of Ca2 is required for VP-dependent adeny-
late cyclase activity; some results [11, 88] suggest such
a requirement while others [84, 89] do not. Since
EGTA was used in all of these studies as the Ca2-
chelating agent, sometimes in high concentration, an
effect of EGTA itself, unrelated to Ca2 binding,
cannot be excluded [17]. Within the millimolar range
of concentration, Ca2 was reported to inhibit the
binding of VP onto plasma membranes [11]. Al-
though it has been reported that Ca2 does not in-
fluence PDIE derived from the renal medulla [90], we
have consistently found that Ca2 increases PDIE
activity in preparations from the renal medulla of
beef and rats (Dousa TP, Hui YSF: unpublished
observations).
5. Other electrolytes and naturally occurring sub-
stances. Adenylate cyclases and cyclic AMP phos-
phodiesterase in general have their pH optima
close to that of blood or slightly to the alkaline side
thereof [17, 57]; the same appears to be true of adeny-
late cyclase derived from the renal medulla [12, 37].
When renal medullary slices from rats were incubated
in acidic media, the VP-induced rise of cyclic AMP
was less than when the medium had a normal pH;
this finding might be causally related to the decreased
antidiuretic response to VP that is seen in acute meta-
bolic acidosis [91].
A number of nonhormonal, naturally occurring
substances have been shown to influence cyclic AMP
metabolism in cell-free systems [17]. They include
guanosine 3 ', 5'-monophosphate (GTP), adenosine
3', 5' triphosphate (ATP), and related nucleotides,
nucleosides and bases [35, 88, 92], and cysteine [93].
It remains to be determined whether these com-
pounds function as cofactors or modulators within
intact cells; for instance, cysteine had a different
effect when added to unbroken tissue [2] than it did
in a cell-free preparation [93].
Cyclic AMP and water permeability
It is generally accepted that the cyclic AMP that is
formed in response to VP administration leads to
increased water permeability. The main argument in
favor of this view is that when the concentration of
cyclic AMP in VP-responsive tissues is increased—
either by adding exogenous nucleotide or its analogs,
or by increasing the endogenous nucleotide through
inhibition of PDIE (Fig. 2)—the actions of VP can be
mimicked [1, 2, 8,9,94]. Furthermore, other adenine
nucleotides, such as 5'-AMP [2, 8], cannot imitate the
effect. Some workers have been reluctant to accept
this evidence because cyclic AMP must be added to
the systems in concentrations that are about 1,000
times higher than those that are measured in vivo.
This objection has been countered, in turn, by point-
ing out that because of the low permeation of cyclic
AMP across cell membranes, a high concentration is
required in the external medium in order to achieve
an effective intracellular level. Chemical analogs of
cyclic AMP [95] to which the cell membrane is more
permeable may eventually help to resolve the argu-
ment. Thus far, N6-02-dibutyryl cyclic AMP
(DBcAMP) is about the only analog that has been
tried. Results with it have been largely equivocal,
probably because it has to be deacylated to N6-mon-
obutyryl cyclic AMP before it can act, or because the
butyrate that is a product of this reaction may have
independent effects that are as yet unknown, or be-
cause DBcAMP may exert its effect principally
through inhibition of PDIE [96]. In renal medullary
extracts, for example, DBcAMP is as potent an inhib-
itor of PDIE on a molar basis as is theophylline
(Dousa TP, Hui YSF: unpublished observations).
Newer analogs of cyclic AMP (mostly substituted at
the C-8 of adenine) that are very active and resistant
to enzymatic breakdown [95] are becoming com-
mercially available, and experiments with these com-
pounds should prove useful [97], For instance, 8(,p -
chloro-phenyl-thio)-cyclic AM P (pClPheS-cAM P),
at concentrations close to physiological (l0°M), acti-
vated protein kinase in intact renal medullary slices,
while exogenous cyclic AMP was barely active at
104M [97]; on the other hand, pClPheS-cAMP does
not differ markedly from cyclic AMP in its ability to
activate protein kinase in cell-free extract [97]. When
applied to microperfused isolated rabbit cortical col-
lecting tubules at a concentration of l05M,pClPheS-
cAMP mimicked the effect of VP on water per-
meability even though inhibitors of PDIE were not
added (Hall D, Grantham JJ: personal communica-
tion).
There have been similar problems with experi-
ments that have sought to raise the intracellular con-
centration of endogenous cyclic AMP by inhibiting
PDIE. Theophylline, which has been most widely
used for this purpose, has other effects such as on
adenylate cyclase [17, 22] or cyclic AMP permeation
[98], which make interpretation of the experiments
equivocal. Again, the use of newer and more potent
inhibitors of PDIE, such as l-methyl-3-isobutyl-xan-
thine [22], may help this problem.
A great deal of work in recent years has centered
about the molecular mechanisms through which cy-
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clic AMP regulates water permeability. Two major
subcellular systems have been considered and tested
experimentally: (1) cyclic AMP-dependent phos-
phorylations of specific membrane proteins and (2)
the role of microtubules and microfilaments. These
systems, which are not mutually exclusive but rather
may complement each other, will be discussed next.
Cyclic AMP-dependent phosphorylation. The func-
tional effects of cyclic AMP in eucaryotic cells may
all be mediated through activation of the enzyme,
cyclic AMP-dependent protein kinase [99—101],
which catalyzes the transfer of y phosphorus from
ATP onto the serine or threonine in side chains of
polypeptides [99, 100]. Although the enzyme appears
to be ubiquitous [101], its involvement has thus far
been proven directly only in the hormonal regulation
of intermediary metabolism [102, 103]. A possible
role of cyclic AM P-dependent phosphorylation in
VP-mediated water permeability has been suggested
for both amphibian [104] and renal [105] epithelial
membranes. According to the hypothesis as it per-
tains to the kidney, water permeability of the luminal
plasma membrane of collecting ducts and late distal
tubules would be associated with a specific membrane
protein, which serves as substrate for cyclic AMP-
dependent protein kinase [105, 106]. Phosphorylation
of this protein would cause a change in the structure
of the membrane, which in turn would increase the
water permeability. The membrane can be returned
to its original resting, relatively water-impermeable
state by enzymatic removal of phosphate from the
protein through the action of protein phosphatase
(Fig. 2).
Experimental work to date has produced some evi-
dence in support of this hypothesis, although proof
for it is still lacking. Bovine renal medulla contains a
cyclic AMP-dependent protein kinase that catalyzes
the phosphorylation of proteins contained in the
plasma membrane of the same tissue [105, 106]; the
medulla also has a protein phosphatase that can re-
move phosphate from the previously phosphorylated
protein [106]. Subcellular fractionation of homoge-
nates from this tissue [33] has revealed the highest
concentration of cyclic AMP-stimulated protein ki-
nase in the fraction containing soluble proteins (cy-
tosol) and very little or no cyclic AMP-dependent
protein kinase in the mitochondrial, microsomal and
plasma membrane fractions. The majority of protein
kinase was also found in soluble proteins of amphib-
ian systems [104]. Cyclic AMP-dependent protein ki-
nase from the bovine medulla has been partially puri-
fied, using standard procedures [106]; protein kinase
activity from the soluble fraction of rabbit renal me-
dulla was further resolved chromatographically into
three different subfractions [107]. Two of these sub-
fractions were cyclic AMP-dependent and preferen-
tially phosphorylated histones. The third one (so-
called PK-llI) was cyclic AMP-independent; it has a
higher substrate affinity for casein, and appears to be
involved in enzymatic inactivation of glycogen syn-
thetase contained in the same tissue [107]. In another
study, done on bovine renal papilla, the protein ki-
nase that is activated by cyclic AMP was reported to
be present not only in cytosol but also in a sub-
fraction of membranes considered to be the luminal
plasma membrane [108]. This membrane subfrac-
tion was reported to be a rather poor substrate
for phosphorylation by cytosolic protein kinase from
the same tissue. In a preliminary communication it is
reported that a protein kinase contained within the
plasma membrane is poorly stimulated by cyclic
AMP, but that the membrane serves as a good sub-
strate for cytosolic protein kinase [109]. According
to another preliminary report, proteins contained
within plasma membranes could be phosphorylated
both by protein kinase located in the membrane and
by cytosolic protein kinase [110]. Thus, it is not yet
clear from these studies, all of which were performed
on cell-free systems, whether the cyclic AM P-depen-
dent protein kinase that catalyzes the phosphoryla-
tion of membrane proteins is an intrinsic component
of the membrane, or whether it is in fact a cytosolic
protein kinase, which becomes loosely associated
with the membrane.
Protein phosphatase activity has also been found
mostly in the soluble fraction (cytosol), and only a
small portion appeared to be associated with the
particulate fractions; no preferential location in one
membrane subfraction over another was found [33].
Dephosphorylating activity could not be detected in
the plasma membrane fractions from bovine renal
papilla [108].
The initial finding [ill] that in the toad bladder VP
or cyclic AMP stimulates protein phosphatase and
thus decreases phosphorylation of a specific protein
seemed to contradict the presumed primary role of
cyclic AMP-dependent protein kinase [106] in regu-
lating VP-induced water permeability. Subsequent
work by the same group [112], however, has identi-
fied this particular protein dephosphorylation as
being associated with VP-stimulated sodium trans-
port rather than with water permeability. For the
moment, then, it appears that cyclic AMP does not
directly influence the activity of protein phosphatase
[33] or protein dephosphorylations in the mamma-
lian renal medulla [108], a view that is in accord with
the concept that protein kinase is the primary regu-
lator [106].
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All of the studies cited above were carried out in
vitro on cell-free components of VP-responsive tis-
sues. The major results have now been substantiated
by experiments utilizing intact cells. When slices of
the renal medulla from beef [51, 113, 114], from rats
[82] or from mice (Kim JK, Hui YSF, Valtin H,
Dousa TP: unpublished observations) are exposed to
VP, protein kinase is activated. The activation is in
direct proportion to the dose of VP used and to the
concentration of cyclic AMP in the slices [511, and it
is specific for VP and cannot be demonstrated for
other hormones [113]. These experiments on renal
medullary slices [51] have yielded an additional inter-
esting result which, however, should be viewed with
caution until it is verified and clarified. After ex-
posure of slices to VP, the total cyclic AMP-depen-
dent protein kinase activity was decreased in the
40,000 X g supernate [51, 114], which contains
mainly soluble proteins [114]. The decrease was spe-
cific for VP-activated protein kinase, and it was di-
rectly correlated with the dose of VP to which the
slices had been exposed and to the tissue content of
cyclic AMP [51]. These results, coupled with our as
yet unpublished observation that VP-activated pro-
tein kinase can be extracted from the 40,000 X g
pellet by use of a buffer with high salt concentration,
may indicate translocation in vivoofcytosolic protein
kinase, or its catalytic subunit [100], and subsequent
binding to specific plasma membrane proteins that
are likely to be contained in the 40,000 X g pellet. The
possibility of nonspecific binding [115], however, has
not yet been ruled out.
Our present knowledge about the role of cyclic
AMP-dependent protein phosphorylation in VP-in-
duced changes of water permeability may be summa-
rized as follows: All of the essential elements for the
phosphorylating and dephosphorylating processes
are present in the target tissue for VP, and the first of
these steps—activation of protein kinase—can be
correlated with the dose of VP used and with the
tissue content of VP-dependent cyclic AMP. The fol-
lowing questions are not yet resolved: (a) Does the
protein kinase that is activated by VP reside in the
plasma membrane and more specifically in the lu-
minal plasma membrane, or is it located in the cy-
toplasm and then translocated onto the membrane
protein? (b) What is the subcellular location of both
the specific protein substrate for VP-activated protein
kinase and of the specific protein phosphatase? (c)
Finally, and most importantly: Is the cyclic AMP-
dependent activation of protein kinase and the sub-
sequent phosphorylation of specific protein(s) caus-
ally related to VP-induced increases in water per-
meability, or is it related only to some ancillary
metabolic adjustments [102, 103], such as glycogen
breakdown, which accompany the action of VP [2, 5]
(Fig. 2)?
Microtubules and microfilaments. In recent years
experimental evidence has been adduced which sug-
gests that the integrity of cytoplasmic microtubules
(MT) and microfilaments (MF) is required for the
cellular action of VP [116—118]. The evidence consists
mainly of the fact that a variety of chemicals that
disrupt MT and MF block the hydroosmotic effect of
VP both in vitro [116, 118—120] and in vivo [117, 121].
1. Microtubules. Cytoplasmic MT appear to be an
invariable component of all eucaryotic cells [122,
123], including those of the kidney [124—126] and
amphibian epithelia [116, 120]. Microtubules are
linear, unbranched structures (Fig. 2), having an out-
side diameter of about 250 A [122, 123]. They are
polymerized from a soluble protein called tubulin,
and the assembled MT exist in a dynamic equilibrium
with free tubulin [122, 123].
A rather large body of indirect evidence points to a
role of MT in VP-induced changes of water per-
meability. Taylor et al [116, 118] first showed that
colchicine, vinblastine and podophyllotoxin—alka-
bids that are known to specifically disrupt MT or to
prevent their assembly [122, 123, 127]—blocked the
increase in osmotic water flow that can normally be
elicited in the toad bladder by VP or by cyclic AMP
[116, 118]. The alkaloids did not inhibit basal water
permeability nor did they affect VP-stimulated Na
transport [116, 118, 120]. Similar observations on
isolated amphibian membranes have been obtained
by others [119, 129]. In conscious, unrestrained rats
colchicine or vinblastine blocked the antidiuretic ac-
tion of VP without an apparent effect on other renal
functions [117], and coichicine also inhibited the re-
sponse to VP in anesthetized rats [120]. Vinblastine
also inhibits the assembly of MT from tubulin in cell-
free extracts [127] as well as intact cells [128, 131]
from the renal medulla. More circumstantial evi-
dence supporting the role of MT in the action of VP
concerns the role of Ca2t Microtubules are easily
disrupted, or their polymerization prevented, by in-
creasing the concentration of ionized Ca2 in the
medium [123, 127]. An increase in extracellular Ca2
[2], or components known to release Ca2 from
intracellular stores or to permit increased entry of
Ca2 from extracellular fluid into the cytoplasm, all
block the effect of VP on the amphibian bladder [2,
130]. In view of these associations, as well as the fact
that hypercalcemia blocks the antidiuretic effect of
VP on the mammalian kidney [3, 6, 90], it is conceiv-
able that an increased concentration of Ca24 disrupts
MT [123, 127]. This possibility is strengthened by the
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finding that high Ca2 blocks the assembly of MT in
both slices and cell-free extracts of the renal medulla
(Dousa TP, Barnes LD: unpublished observations).
The mode whereby MT are involved in VP-con-
trolled water permeability is not yet known. In-
asmuch as the alkaloids that interfere with MT block
the effect not only of VP but also of cyclic AMP [116,
119, 120], and since nonhormonal increases in water
permeability are not blocked by these alkaloids [129],
the involvement of MT presumably lies in steps distal
to the formation of cyclic AMP. Consistent with this
view is the finding that the alkaloids do not interfere
with enzymes involved in either the metabolism or
action of VP-dependent cyclic AMP in the renal me-
dulla in vitro [117].
Microtubules might be involved in the control of
water permeability by one or both of two general
mechanisms [117]: (a) they may not be influenced by
VP-dependent cyclic AMP, but instead might serve as
a cytoplasmic lattice (cytoskeleton), which deter-
mines the subcellular localization and directs the
translocation of other components that regulate wa-
ter permeability; or (b) their structure and function
might be influenced by VP-dependent cyclic AMP,
and they might affect water permeability within the
membrane more directly by interacting with other
components. There are as yet no data that clearly
favor one mechanism over the other. Exposure of
toad bladders to VP caused a small but significant
increase in the volume density of MT, whereas ex-
posure to colchicine led to a profound decrease
[132]. While the first change was accompanied by
increased water permeability, this function was not
altered when colchicine alone was given [132]. Thus,
the functional meaning of the structural changes is
not clear; it might mean that only a certain portion of
the total complement of MT is related to the control
of water permeability. Neither cyclic AMP nor VP
appeared to affect the polymerization of MT from
tubulin, whether this effect was tested on slices [128,
131] or in cell-free extracts of the renal medulla [127].
Although the alkaloids that bind to tubulin and
thereby disrupt MT do not influence the phosphory-
lating [110, 117] or dephosphorylating [134] proc-
esses, there may nevertheless be some relationships
between tubulin and protein kinase [123]. On the
basis of purification procedures, it appears that tubu-
lin and protein kinase are closely associated, both in
brain [135] and in kidney extracts (Barnes LD, Dousa
TP: unpublished observations). Furthermore, analy-
sis of preparations from brain suggests that tubulin
has an enzymatic activity like that of cyclic AMP-
dependent protein kinase, and that the substrate for
enzymatic phosphorylation appears to be a protein
that is closely associated with tubulin [135]; it is not
yet known whether phosphorylation of this protein
influences the structure or function of MT. On the
other hand, VP administration in vivo causes the
activation and apparent translocation of soluble pro-
tein kinase in the renal medulla, although apparently
it does not simultaneously induce translocation of
tubulin in this tissue [51] as assessed by [3H]-colchi-
cine binding activity.
On concluding this section, it should be stressed
that although VP and hence cyclic AMP apparently
do not influence the formation (polymerization) of
MT from tubulin in any major way, it is conceivable
that they might alter properties of these structures
other than those that were tested in the above studies.
Such properties might include spatial rearrangement
of MT within cells, structural stability, or loose inter-
action of MT with plasma membranes. Until these
and other possibilities have been investigated, any
conclusion of how VP might influence water per-
meability through the intermediation of MT seems
premature.
2. Microfilamenis (MF). These organelles are fi-
brous, linear structures that have a smaller diameter
(about 50 A) than do MT. Microfilaments are com-
posed of proteins with biochemical properties similar
to those of muscle actin [136]. They are found in
considerable quantities in renal tubular cells, includ-
ing those of collecting ducts [124, 125]. Unlike MT,
MF frequently terminate close to cell membranes or
even seem to be attached to them [119, 123, 125] (Fig.
3). In analogy with the use of alkaloids in studying
MT, the involvement of MF in cellular function has
been studied using cytochalasins, antibiotics that dis-
rupt the structure of MF. Cytochalasin B (Cyt B),
which is most frequently used experimentally, may
also influence functions that do not involve inter-
action with MF—e.g., hexose transport [137, 138].
However, these other effects are seen at different dos-
ages than those that interfere with MF, and the vari-
ous responses can therefore be segregated [138].
In amphibian membranes, Cyt B has been shown
to reversibly inhibit the hydroosmotic effect of either
VP [116, 119, 120, 139, 140] or of exogenous cyclic
AMP [116, 119], and also to blunt the VP-induced
increase of endogenous cyclic AMP [139]. Although
Cyt B, used either alone or in combination with VP,
does not alter the active transport of Na [116, 120],
it does increase the flux of some solutes, such as Na,
Cl and urea, and it decreases the electrical potential
difference across the epithelium [116, 139].
The use of Cyt B in conjunction with VP causes
some striking morphological changes that are not
observed when VP is used alone. The hydroosmotic
Fig. 3. Hypothetical role of microfilaments in
VP-dependent transcellular water flow. VP,
vasopressin; MF, microfilaments; LuPM, lu-
minal plasma membrane; BM, basement
membrane. A, in the absence of VP; B, VP-
induced transepithelial water flow; C, VP
effect in the presence of cytochalasin B,
which disrupts possible connections of MF
with the lateral plasma membrane. We
emphasize that the drawings are schematic
and that they portray a tentative hypothesis,
especially part C.
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effect of VP alone is accompanied by widening of the
lateral intercellular spaces (Fig. 3), which presum-
ably reflects the importance of intercellular pathways
in the transepithelial flow of water [141-144]. When
the tissue is exposed to Cyt B and then to VP, how-
ever, the most pronounced changes include an accu-
mulation of giant vacuoles that appear to be located
within the cells (Fig. 3c) [139]; in addition, there is
disruption of the orderly association of MF with
basolateral membranes [119] and changes in the
membrane that are indicative of cell swelling [139,
145]. Microfilaments may be contractile elements
[136, 137], and their attachment to the basolateral or
predominantly to the lateral plasma membrane (Fig.
3a) may have functional significance. It is possible,
therefore, that MF may play a role in VP-induced
transcellular flux of water by altering the properties
of lateral membranes in such a way as to increase the
passive flow of solutes and water across these bar-
riers, thereby causing the formation of intercellular
spaces as a pathway for water flow. In this context,
the formation of large intracellular vacuoles [139]
and cell swelling [145] when Cyt B is given in con-
junction with VP may reflect an inability of water to
enter the lateral intercellular spaces (Fig. 3c). By
disrupting MF, Cyt B might thus hinder transcellular
water flux even though Cyt B might not interfere with
VP-induced or cyclic-AMP-induced changes in the
water permeability of the luminal plasma membrane
[145]. In preliminary studies thus far, it has not been
possible to demonstrate an inhibitory effect of Cyt B
on VP-induced antidiuresis in rats [134], but there
may be some simple explanation for this failure, such
as insufficient dosage of Cyt B. Obviously, however,
the above speculations, derived from observations in
amphibians, should be viewed with caution until
more data become available.
The VP-controlled barrier to water flow
The luminal plasma membrane (LuPM) is appar-
ently the major barrier whose permeability for water
can be altered by VP (Figs. I and 2) [1, 142, 146]. In
this section, we shall review the properties of this
membrane, and we shall speculate on how some of
the biochemical processes that we have discussed,
such as phosphorylation and changes in MT and MF,
might be related to VP-induced alterations of the
LuPM. So-called "tight junctions" are interposed be-
tween the LuPM of adjacent cells (Fig. 2). Although
these specialized structures permit the passage of lan-
thanum in medullary collecting ducts [147], the junc-
tions appear to be generally impermeable to water
and solutes [1, 2, 141, 142], and in any case their
permeability properties are not influenced by VP
[1471.
One central question on this topic concerns the
route for the passage of water through the LuPM
[1—4]. On the basis of a series of elegant studies on
anuran membranes [148] and the mammalian neph-
ron [8], it was proposed that bulk flow of water takes
place mainly through pores in the membrane, and
that VP increases either the size or the number of
these channels. Findings of more recent experiments
suggest an alternate or additional explanation [3, 4,
149—152]. If the effect of unstirred layers is taken into
account—either of water on the outer surface of the
LuPM [149] or of cytoplasm on the inner surface [1,
149, 1501—then it may be possible to explain the
effect of VP on the flux of water by changes in the
diffusional permeability of the membrane, without
having to invoke the structural entity of pores and
changes in bulk flow. It is not yet clear which view is
the correct one.
A number of mechanical and ultrastructural
changes of the LuPM have been correlated with VP-
induced increases of water permeability. Grantham
[153] observed enhanced deformability of the LuPM
when isolated, perfused collecting ducts were exposed
to either VP or to an analog of cyclic AMP. In-
asmuch as polymerization of MT in vitro profoundly
alters the viscosity of the aqueous solution [154, 155],
it might be suspected that the change in deformability
of the LuPM is secondary to an alteration in the
components, possibly MT, of the submembranal
layers of cytoplasm. Grantham [1] has found, how-
ever, that the viscosity of the cytoplasm was not
changed by VP administration; thus, the VP-induced
increase in deformability appears to be intrinsic to
the LuPM.
Ultrastructural alterations that are associated with
VP have thus far been described mainly for apical
membranes of granular cells from anuran urinary
bladders, which are analogous to the LuPM of mam-
malian collecting tubules. Scanning electron micros-
copy has revealed that before exposure to VP, these
membranes have many branching ridges and small
globular structures that occur in clumps or chains
[145, 156]. Administration of VP appears to abolish
the ridges and to cause the emergence of numerous
microprojections, apparently microvilli [156]; VP or
cyclic AMP also produce an increase in exocytosis
[157]. The fact that these changes were observed even
in the absence of an osmotic gradient across the
epithelium suggests that they occurred primarily and
specifically in response to VP.
Like other membranes, the apical membrane of
granular cells from amphibian urinary bladders can
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be separated into two leaflets by the freeze-fracture
technique: the inner leaflet A, which faces the interior
of the cell, and the outer leaflet B [158—160]. In the
apical membrane, intramembranous particles are
more numerous on leaflet B than on leaflet A,
whereas the opposite is true in basolateral mem-
branes [158, 159]. Exposure of the tissues to oxytocin
[158] or to VP [159, 160] causes striking changes in
the distribution of these particles. Without hormone,
the intramembranous particles are evenly dispersed,
while with hormone the particles are aggregated into
clusters of linear arrays [158, 160]. These changes
were found to be specific for the apical membrane
[158, 160] and for VP-induced water transport as
opposed to urea or sodium transport [161], they were
confined to cells that respond to VP [160] and they
could be reversed by removal of the hormone [158].
Furthermore, the frequency of aggregation sites was
positively correlated with the degree of VP-stimu-
lated osmotic water flow [160]. The findings, there-
fore, suggest a specific structural reorganization
within the membrane that specifically reflects VP-
induced changes in water permeability. This thesis
needs to be tested in mammalian collecting ducts, in
which modulation of permeability may be the only
function of VP. Thus far, only one report about
intramembranous particles in mammalian collecting
ducts has appeared, and the response to VP was not
tested in this study [162].
The possibility that VP-induced ultrastructural
changes may be causally related to changes in the
permeability of the membrane appears to be consist-
ent with findings from experiments with tissue fix-
atives. When VP-sensitive cells were exposed to gluta-
raldehyde, they were "locked" into the state of
permeability that prevailed at the time of exposure,
be that low permeability in the basal state or high
permeability after VP administration [163, 164].
Glutaraldehyde "fixes" proteins and other macro-
molecules by nonspecific covalent cross-linking. The
above findings are, therefore, consistent with the view
that glutaraldehyde prevents alterations in the per-
meability of the LuPM by blocking intramembranal
structural changes that can be observed at the ultra-
structural level.
At the present state of our knowledge, it is per-
missible, we think, to speculate on the possible rela-
tionship of cyclic AMP-dependent phosphorylation
and the structural integrity of MT and MF to the
observed ultrastructural features of the LuPM. Phos-
phorylation can profoundly alter the physico-
chemical properties of a polypeptide. The increase in
the number of negative charges, as well as in the size
of a polypeptide resulting from the covalent attach-
ment of phosphorus to the side chains of serine and
threonine, can conceivably modify the secondary and
tertiary structure of the protein and influence its in-
teractions with other components of the membrane.
Such interactions could conceivably be affected
whether the specific protein that is phosphorylated
resides in the cytoplasm adjacent to the membrane
(and subsequently influences intrinsic elements of the
membrane), or whether the protein is itself an in-
tegral component of the membrane structure.
VP-induced aggregation of intramembranous par-
ticles [158, 160] which may be proteins might well be
related as a cause or consequence of increased fluidity
of VP-sensitive plasma membranes [4, 152, 165], and
the fluidity, in turn, could conceivably be associated
with increased diffusional permeability of these mem-
branes for water [149—151]. It is through that chain of
events that MT might influence membrane per-
meability. According to the fluid mosaic model of
membrane structure, membrane proteins may move
within a lipid matrix [166]. Such movement of in-
tramembranous particles or changes in membrane
fluidity, or both, may depend on the integrity of MT,
for it has been shown that alkaloids which disrupt
MT alter the topographical distribution of certain
proteins at the cell surface [167—170]. On the basis of
these findings, Berlin et al [167, 169, 170] and Yahara
and Edelman [168] have suggested that MT may
restrain or direct coordinated movement of mem-
brane proteins. If intramembranous particles are
proteins, MT might direct or otherwise condition
the VP-induced aggregation of these particles
within the LuPM [158, 160].
As was the case with specific phosphoproteins, it is
not yet clear just how MT may interact with the
LuPM. Even though MT as well as their monomer
protein, tubulin, are located mainly in the cytoplasm
of VP-responsive tissues [117, 120], and even though
a direct connection between MT and plasma mem-
branes has not been observed morphologically [124,
125], some type of loose interaction of MT with the
membrane is by no means ruled out. In fact, the
recent finding that some tubulin is built up in the
plasma membrane [171] opens the possibility that
intramembranous tubulin might serve as a point of
contact for MT with the LuPM. Also, MT are highly
labile structures and, hence, such associations might
thus far have eluded experimental detection.
Finally, it is tempting to speculate that the sites of
aggregated intramembranous particles, possibly pro-
teins, may be the loci of increased membrane fluidity
and, hence, of increased diffusional permeability for
water in the LuPM [161]. In a sense, this proposal
might reconcile the two seemingly incompatible views
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concerning the route of transepithelial water trans-
port, retaining some features of each: VP would not
increase bulk flow through specific mechanical chan-
nels in the LuPM, but it would enhance diffusion by
increasing the diffusional permeability at specific
areas within the membrane. In other words, the
primary mechanism of water permeation would be an
increase in diffusional water permeability, but in spe-
cifically localized areas or "functional pores" rather
than randomly throughout the entire surface of the
membrane.
As we proposed in connection with Fig. 3, MF may
not directly influence the water permeability of the
LuPM; instead, they may influence the properties
of the basolateral membrane so that the preferen-
tial flow of water through lateral intercellular spaces
is hindered when MF are disrupted. Although it is
not known just how MF might affect the baso-
lateral membrane, the fact that these filaments
appear to be contractile elements [136, 137] sug-
gests some sort of active role.
Conclusions
A surge of experimental work during the past 10 to
15 yr has greatly expanded our knowledge about the
cellular action of VP. At the present time there is
much evidence which justifies the schema depicted in
Fig. 2, at least as a working hypothesis for the imme-
diate future. There is little doubt that the effect of VP
is mediated through cyclic AMP, although many as-
pects of VP-dependent cyclic AMP metabolism re-
main to be solved—e.g., the exact chemical structure
of the VP-receptor and of the enzymes for cyclic
AMP metabolism, and the intracellular location of
cyclic AMP. Almost certainly cyclic AMP-dependent
protein phosphorylation is involved, in one way or
another, in the induction of increased water per-
meability. Microtubules and microfilaments have
been identified as important and possibly essential
components in the action of VP. Ultrastructural anal-
ysis of the cellular components that serve as a barrier
for water permeation, especially the luminal plasma
membrane, has just begun.
There is much criticism these days about the lag
between discoveries in the basic biomedical sciences
and their application to pathological states. Perhaps
this criticism cannot be leveled at the area of the
cellular action of VP, where new findings in basic
hormonal mechanisms have been almost immediately
applied to clarifying the pathogenesis and treatment
of diseases with anomalous responsiveness to VP [6,
172]. It is probably not too farfetched to hope that as
the defects in these diseases are localized to one or
more particular steps in the cellular action of VP
(Fig. 2), a specific form of therapy may be designed.
For example, unresponsiveness to VP—as in he-
reditary nephrogenic diabetes insipidus in mice [87,
1 731—or decreased responsiveness—as in chronic hy-
pothalamic diabetes insipidus [59], hypercalcemia
[11, 66, 90], hypothyroidism [82] or similar syn-
dromes caused by various drugs [1741—might be due,
at least in part, to deficient formation of cyclic AMP.
In diseases of this type, newer chemical analogs of
cyclic AMP [95, 97J might conceivably be used to
compensate for deficient endogenous concentrations
of the nucleotide. Chlorpropamide, which was pre-
viously shown to potentiate the effect of VP in vivo
[175, 176], appears to act through sensitization of ad-
enylate cyclase to VP [177] (Barnes LD, Dousa TF:
unpublished observations) and/or possibly through
inhibition of PDIE [178]. As has been true of VP-
analogs, it is possible that new derivatives of chlor-
propamide, with higher VP-sensitizing potency and
lower hypoglycemic effects, might be developed. In
other types of resistance to VP, as in potassium deple-
tion [53, 179], the major defect may lie in steps sub-
sequent to the generation of cyclic AMP [6]; such
syndromes will require a different therapeutic ap-
proach. At the other end of the spectrum, new under-
standing of the cellular action of VP is being applied
to conditions that involve a surfeit of VP. It has been
suggested, for example, that drugs such as deme-
clocycline and lithium, which inhibit the action of
VP [6, 174], might be useful in treating the syndrome
of inappropriate antidiuretic hormone secretion
[180—183]. These facets of the subject are discussed in
much greater detail in another contribution to this
symposium [174].
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